Literature DB >> 8534757

Levels of the terminal complement complex, C3a-desArg and C1-inhibitor in adult patients with capillary leak syndrome following bone marrow transplantation.

C Salat1, E Holler, M Schleuning, B Eisele, B Reinhardt, H Kolb, R Pihusch, R Domrath, E Hiller.   

Abstract

Capillary leak syndrome (CLS) is a severe complication after bone marrow transplantation (BMT). To investigate whether there is a pathogenetic role of the complement system, we monitored the levels of the terminal complement complex C5b-9 (TCC) and C3a-desArg as indicators of an activation of the complement system and the inhibitor of the classical pathway of the complement cascade, C1 inhibitor (C1-INH), in 48 bone marrow transplant recipients from 1 week before to 5 weeks after transplantation. Capillary leak syndrome developed in 7 out of 48 patients between days 1 and 12 after BMT. Complement activation as indicated by TCC levels was more pronounced in patients with CLS (n = 7) from day -8 to +28 (p < 0.05; day -1) and the elevation of TCC levels lasted longer in CLS patients (peak day 21) than in patients without this complication (peak day 7). Mean C3a-desArg levels were highest in patients with CLS reaching a peak at day 7. During the early posttransplant period a significant elevation of C1-INH levels (p < 0.01 and p < 0.05 respectively) compared with baseline levels (day -8) was found in patients with and without CLS, which was more pronounced in those patients with CLS (p < 0.05). Although we could not observe an absolute C1-INH deficiency as compared to healthy individuals our data support the presence of a relative deficiency of the inhibitor which might explain the reported beneficial effects of C1-INH substitution in BMT related CLS.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8534757     DOI: 10.1007/bf01697978

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  6 in total

1.  Activation of the complement system during immunotherapy with recombinant IL-2. Relation to the development of side effects.

Authors:  L G Thijs; C E Hack; R J Strack van Schijndel; J H Nuijens; G J Wolbink; A J Eerenberg-Belmer; H Van der Vall; J Wagstaff
Journal:  J Immunol       Date:  1990-03-15       Impact factor: 5.422

2.  Adoptive immunotherapy of human cancer: the cytokine cascade and monocyte activation following high-dose interleukin 2 bolus treatment.

Authors:  G Boccoli; R Masciulli; E M Ruggeri; P Carlini; G Giannella; E Montesoro; G Mastroberardino; G Isacchi; U Testa; F Calabresi
Journal:  Cancer Res       Date:  1990-09-15       Impact factor: 12.701

3.  Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation.

Authors:  E Holler; H J Kolb; A Möller; J Kempeni; S Liesenfeld; H Pechumer; W Lehmacher; G Ruckdeschel; B Gleixner; C Riedner
Journal:  Blood       Date:  1990-02-15       Impact factor: 22.113

4.  Activity of C1 esterase inhibitor in patients with vascular leak syndrome after bone marrow transplantation.

Authors:  W Nürnberger; I Michelmann; K Petrik; S Holthausen; R Willers; G Lauermann; B Eisele; U Delvos; S Burdach; U Göbel
Journal:  Ann Hematol       Date:  1993-07       Impact factor: 3.673

5.  Synthesis of complement components (C3, C2, B and C1-inhibitor) and lysozyme by human monocytes and macrophages.

Authors:  D Lappin; A D Hamilton; L Morrison; M Aref; K Whaley
Journal:  J Clin Lab Immunol       Date:  1986-07

6.  The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2.

Authors:  J W Baars; C E Hack; J Wagstaff; A J Eerenberg-Belmer; G J Wolbink; L G Thijs; R J Strack van Schijndel; H L van der Vall; H M Pinedo
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640

  6 in total
  4 in total

Review 1.  Engraftment syndrome: double-edged sword of hematopoietic cell transplants.

Authors:  T R Spitzer
Journal:  Bone Marrow Transplant       Date:  2015-01-12       Impact factor: 5.483

Review 2.  C1 inhibitor: molecular and clinical aspects.

Authors:  Marco Cicardi; Lorenza Zingale; Andrea Zanichelli; Emanuela Pappalardo; Benedetta Cicardi
Journal:  Springer Semin Immunopathol       Date:  2005-11-11

3.  Adaptive Immune Response Impairs the Efficacy of Autologous Transplantation of Engineered Stem Cells in Dystrophic Dogs.

Authors:  Clementina Sitzia; Andrea Farini; Luciana Jardim; Paola Razini; Marzia Belicchi; Letizia Cassinelli; Chiara Villa; Silvia Erratico; Daniele Parolini; Pamela Bella; Joao Carlos da Silva Bizario; Luis Garcia; Marcelo Dias-Baruffi; Mirella Meregalli; Yvan Torrente
Journal:  Mol Ther       Date:  2016-08-10       Impact factor: 11.454

4.  Incidence of Capillary Leak Syndrome as an Adverse Effect of Drugs in Cancer Patients: A Systematic Review and Meta-Analysis.

Authors:  Gwang Hun Jeong; Keum Hwa Lee; I Re Lee; Ji Hyun Oh; Dong Wook Kim; Jae Won Shin; Andreas Kronbichler; Michael Eisenhut; Hans J van der Vliet; Omar Abdel-Rahman; Brendon Stubbs; Marco Solmi; Nicola Veronese; Elena Dragioti; Ai Koyanagi; Joaquim Radua; Jae Il Shin
Journal:  J Clin Med       Date:  2019-01-26       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.